Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.
|Articles|July 14, 2015
3M Launches Production-Scale Sizes of its Upstream Purifiers
Author(s)BioPharm International Editors
The new sizes follow the 2014 launch of the company’s fully disposable purifier.
Advertisement
3M announced the launch of production-scale variants of its year-old upstream product, the Emphaze AEX Hybrid. The new sizes can accommodate process volumes of up to 25,000 liters.
According to the company, use of the purifier can reduce host-cell protein load by 25–35% and helps increase Protein A column output purity while requiring less aggressive column cleaning, effectively extending the life of a chromatography column.
Source: 3M
Advertisement
Related to this article
Donidalorsen sustained a 95% reduction in hereditary angioedema attacks over 2 years, and patients switching from other prophylaxis saw a 71% drop.
FDA has effectively paused its Commissioner’s National Priority Voucher pilot and appears to have halted new complete response letter postings, according to reports. HHS says work on the program is ongoing.
A single 240 mg dose of WVE-007 cut visceral fat while preserving lean mass for 1 year, as Activin E fell by up to 88% across INLIGHT dose groups.
A single dose of Zai Lab’s long-acting bispecific ZL-1503 produced at least 90% inhibition of an atopic dermatitis signaling biomarker through Week 12 in healthy volunteers. Its 40- to 50-day half-life supports a target of dosing every 12 weeks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
Advertisement
Advertisement
Trending on BioPharm International
1
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
2
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
3
enGene Plans Year-End BLA for Detalimogene in BCG-Unresponsive NMIBC
4
Sponsors Should Plan CMC Earlier When a First-in-Human Study Could Be Pivotal, Says Former FDA Reviewer Paz Vellanki
5